Blumlein S L, Sievers R, Kidd P, Parmley W W
Am J Cardiol. 1984 Oct 1;54(7):884-9. doi: 10.1016/s0002-9149(84)80226-x.
Seventy-two rabbits were separated into groups to receive no drug, subcutaneous verapamil, metoprolol, hydralazine, metoprolol and hydralazine, or oral verapamil in 1 of 3 doses daily for 10 weeks. They also received a high-cholesterol diet and had serum triglyceride, cholesterol, and verapamil levels measured twice during the study. Blood pressure (BP), heart rate and weight were measured every 10 days. Approximately 60% of the rabbits given verapamil had detectable levels of the drug in their serum. This group had significantly less severe atherosclerosis in their aortas at the time they were killed, even though they had significantly higher cholesterol levels than the other groups. This group also did not have different BP than the other groups (except for the subcutaneous verapamil group). Thus, protection from atherosclerosis by verapamil in the cholesterol-fed rabbit is not the result of lowering of BP.
72只兔子被分成不同组，分别不接受药物治疗、皮下注射维拉帕米、美托洛尔、肼屈嗪、美托洛尔和肼屈嗪联合治疗，或每日3种剂量之一的口服维拉帕米，持续10周。它们还接受高胆固醇饮食，并在研究期间两次测量血清甘油三酯、胆固醇和维拉帕米水平。每10天测量血压（BP）、心率和体重。给予维拉帕米的兔子中约60%血清中可检测到该药物水平。该组兔子在处死时主动脉粥样硬化程度明显较轻，尽管它们的胆固醇水平明显高于其他组。该组兔子的血压与其他组也没有差异（皮下注射维拉帕米组除外）。因此，在喂食胆固醇的兔子中，维拉帕米对动脉粥样硬化的保护作用并非降低血压的结果。
